This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
by Indrajit Bandyopadhyay
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
by Zacks Equity Research
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
by Zacks Equity Research
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA
by Zacks Equity Research
The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.
Mirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
by Zacks Equity Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
by Zacks Equity Research
Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
by Zacks Equity Research
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
by Zacks Equity Research
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
by Zacks Equity Research
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
by Zacks Equity Research
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Here's Why Sarepta Therapeutics (SRPT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051
by Zacks Equity Research
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.
Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.